Skip to main content
Premium Trial:

Request an Annual Quote

Biotage Inks Distribution, R&D Pacts with MultiSynTech

NEW YORK (GenomeWeb News) — Under two new agreements it has struck with the German company MultiSynTech, Biotage will join the peptide synthesis market, the Swedish biotech firm said today.

Through one agreement, Biotage has acquired distribution rights to all of MultiSynTech's robotic peptide synthesis systems.

The companies also will work together on a development project to design and market a microwave-aided peptide synthesis system, with the goal of increasing the yield and speed of the peptide synthesis process. The system will integrate Biotage's microwave technology with MutiSynTech's robotic synthesizer technology, the firms said. Customers for the system will include university and biopharmaceutical research groups and contract labs.

These agreements will allow Biotage, which also has operations in the US, Japan, the UK, and Germany, to offer parallel synthesis and microwave synthesis.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.